Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Title of each class |
Trading Symbols(s) |
Name of each exchange on which registered |
Large accelerated filer: | ☐ | Accelerated filer: | ☐ | |||
☐ (Do not check if a smaller Reporting company) | Smaller reporting company: | |||||
Emerging growth company: |
Page No. |
||||||
Part I: |
||||||
Item 1. |
||||||
3 |
||||||
4 |
||||||
5 |
||||||
6 |
||||||
7 – 32 |
||||||
Item 2. |
33 – 46 |
|||||
Item 3. |
46 |
|||||
Item 4. |
46 |
|||||
Part II: |
||||||
Item 1. |
46 |
|||||
Item 1A. |
46 |
|||||
Item 2. |
46 |
|||||
Item 4. |
46 |
|||||
Item 5. |
46 |
|||||
Item 6. |
47 |
|||||
48 |
Unaudited June 30, 2021 |
December 31, 2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Accounts receivable and other, net |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
|
|
|
|
|||||
PROPERTY AND EQUIPMENT |
||||||||
Equipment and office fixtures |
||||||||
Right to use – operating lease, net |
||||||||
Accumulated depreciation |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total property and equipment |
||||||||
|
|
|
|
|||||
NON-CURRENT ASSETS |
||||||||
Investment in unconsolidated entity |
||||||||
Exploration license |
||||||||
Other non-current assets |
||||||||
|
|
|
|
|||||
Total non-current assets |
||||||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) |
||||||||
CURRENT LIABILITIES |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Operating lease obligation |
||||||||
Loans payable |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
|
|
|
|
|||||
LONG-TERM LIABILITIES |
||||||||
Loans payable |
||||||||
Operating lease obligation |
||||||||
Deferred income and revenue participation rights |
||||||||
|
|
|
|
|||||
Total long-term liabilities |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
|
|
|
|
|||||
Commitments and contingencies (NOTE H) |
||||||||
STOCKHOLDERS’ EQUITY/(DEFICIT) |
||||||||
Preferred stock - $ |
||||||||
Common stock – $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated (deficit) |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity/(deficit) before non-controlling interest |
( |
) | ( |
) | ||||
Non-controlling interest |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity/(deficit) |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total liabilities and stockholders’ equity/(deficit) |
$ | $ | ||||||
|
|
|
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30, 2021 |
June 30, 2020 |
June 30, 2021 |
June 30, 2020 |
|||||||||||||
REVENUE |
||||||||||||||||
Service revenue and other |
$ | $ | $ | $ | ||||||||||||
Expedition |
— | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total revenue |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES |
||||||||||||||||
Marketing, general and administrative |
||||||||||||||||
Operations and research |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
INCOME (LOSS) FROM OPERATIONS |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
OTHER INCOME (EXPENSE) |
||||||||||||||||
Interest expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Loss in hybrid-instrument fair value |
— | ( |
) | — | ( |
) | ||||||||||
Other |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense) |
( |
) | ( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(LOSS) BEFORE INCOME TAXES |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Income tax benefit (provision) |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET (LOSS) BEFORE NON-CONTROLLING INTEREST |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Non-controlling interest |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
NET (LOSS) |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
|
|
|
|
|
|
|
|||||||||
NET (LOSS) PER SHARE |
||||||||||||||||
Basic and diluted (See NOTE B) |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
|
|
|
|
|
|
|
|||||||||
Weighted average number of common shares outstanding |
||||||||||||||||
Basic |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Diluted |
||||||||||||||||
|
|
|
|
|
|
|
|
Three Months Ended June 30, 2021 |
||||||||||||||||||||
Common Stock |
Additional Paid- in Capital |
Accumulated Deficit |
Non-controlling Interest |
Total |
||||||||||||||||
March 31, 2021 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||
Share-based compensation |
— | — | — | |||||||||||||||||
Net (loss) |
( |
) | ( |
) | ( |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
June 30, 2021 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Three Months Ended June 30, 2020 |
||||||||||||||||||||
Common Stock |
Paid-in Capital |
Accumulated Deficit |
Non-controlling Interest |
Total |
||||||||||||||||
March 31, 2020 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||
Share-based compensation |
||||||||||||||||||||
Fair value of warrants issued |
||||||||||||||||||||
Net (loss) |
( |
) | ( |
) | ( |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
June 30, 2020 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Six Months Ended June 30, 2021 |
||||||||||||||||||||
Common Stock |
Paid-in Capital |
Accumulated Deficit |
Non-controlling Interest |
Total |
||||||||||||||||
December 31, 2020 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||
Share-based compensation |
||||||||||||||||||||
Common stock issued for converted convertible debt |
||||||||||||||||||||
Common stock issued for services |
||||||||||||||||||||
Sale of subsidiary equity |
||||||||||||||||||||
Net (loss) |
— | ( |
) | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
June 30, 2021 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Six Months Ended June 30, 2020 |
||||||||||||||||||||
Common Stock |
Paid-in Capital |
Accumulated Deficit |
Non-controlling Interest |
Total |
||||||||||||||||
December 31, 2019 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||
Share-based compensation |
||||||||||||||||||||
Fair value of warrants issue |
||||||||||||||||||||
Net (loss) |
— | ( |
) | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
June 30, 2020 |
$ | $ | $ |
( |
) | $ | ( |
) | $ |
( |
) | |||||||||
|
|
|
|
|
|
|
|
|
|
Six-Months Ended |
||||||||
June 30 2021 |
June 30 2020 |
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
Net loss before non-controlling interest |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash (used) by operating activities: |
||||||||
Investment in unconsolidated entity |
( |
) | — | |||||
Depreciation and amortization |
||||||||
Financed lender fee amortization |
||||||||
Note payable interest accretion |
( |
) | ( |
) | ||||
Right of use amortization |
||||||||
Share-based compensation |
||||||||
Change in hybrid-instrument fair value |
— | |||||||
Deferred income |
( |
) | — | |||||
(Increase) decrease in: |
||||||||
Accounts receivable |
( |
) | ( |
) | ||||
Other assets |
||||||||
Increase (decrease) in: |
||||||||
Accounts payable |
||||||||
Accrued expenses and other |
||||||||
|
|
|
|
|||||
NET CASH (USED) BY OPERATING ACTIVITIES |
( |
) | ( |
) | ||||
|
|
|
|
|||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
Purchase of property and equipment |
( |
) | — | |||||
|
|
|
|
|||||
NET CASH (USED) PROVIDED BY INVESTING ACTIVITIES |
( |
) | — | |||||
|
|
|
|
|||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
Proceeds from issuance of notes payable |
||||||||
Operating lease liability reduction |
( |
) | ( |
) | ||||
Sale of subsidiary equity |
— | |||||||
Payment of debt obligation |
( |
) | ( |
) | ||||
|
|
|
|
|||||
NET CASH (USED) PROVIDED BY FINANCING ACTIVITIES |
||||||||
|
|
|
|
|||||
NET INCREASE (DECREASE) IN CASH |
( |
) | ||||||
CASH AT BEGINNING OF PERIOD |
||||||||
|
|
|
|
|||||
CASH AT END OF PERIOD |
$ | $ | ||||||
|
|
|
|
|||||
SUPPLEMENTARY INFORMATION: |
||||||||
Interest paid |
$ | $ | — | |||||
Income taxes paid |
$ | $ | — | |||||
NON-CASH TRANSACTIONS: |
||||||||
Director compensation settled with equity |
$ | $ | ||||||
Accrued interest settled with common stock |
$ | $ | — |
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30, 2021 |
June 30, 2020 |
June 30, 2021 |
June 30, 2020 |
|||||||||||||
Average market price during the period |
$ | $ | $ | $ | ||||||||||||
In the money potential common shares from options excluded |
||||||||||||||||
In the money potential common shares from warrants excluded |
Three Months Ended |
Six Months Ended |
|||||||||||||||
Per share exercise price |
June 30, 2021 |
June 30, 2020 |
June 30, 2021 |
June 30, 2020 |
||||||||||||
Out of the money options excluded: |
||||||||||||||||
$ |
||||||||||||||||
$ |
||||||||||||||||
$ |
||||||||||||||||
Out-of-the-money |
||||||||||||||||
$ |
||||||||||||||||
Total excluded |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30, 2021 |
June 30, 2020 |
June 30, 2021 |
June 30, 2020 |
|||||||||||||
Potential common shares from unvested restricted stock awards excluded from EPS |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30, 2021 |
June 30, 2020 |
June 30, 2021 |
June 30, 2020 |
|||||||||||||
Net income (loss) |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Numerator, basic and diluted net income (loss) available to stockholders |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Denominator: |
||||||||||||||||
Shares used in computation – basic: |
||||||||||||||||
Weighted average common shares outstanding |
||||||||||||||||
Common shares outstanding for basic |
||||||||||||||||
Shares used in computation – diluted: |
||||||||||||||||
Common shares outstanding for basic |
||||||||||||||||
Shares used in computing diluted net income per share |
||||||||||||||||
Net (loss) per share – basic |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Net (loss) per share – diluted |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) |
June 30, 2021 |
December 31, 2020 |
|||||||
Related party |
||||||||
Other |
— | |||||||
|
|
|
|
|||||
Total accounts receivable and other |
$ | $ | ||||||
|
|
|
|
Fair value of |
$ | |||
Direct transaction costs |
||||
|
|
|||
Total consideration paid |
$ | |||
|
|
Intangible asset- |
$ | |||
Current assets |
||||
Current liabilities |
( |
) | ||
Less: Non-controlling interest |
( |
) | ||
|
|
|||
Total net assets acquired |
$ | |||
|
|
June 30, 2021 |
$ | |||
December 31, 2020 |
||||
Change in valuation allowance |
$ | |||
Year ending December 31, |
Annual payment obligation |
|||
2021 |
||||
2022 |
||||
2023 |
||||
2024 |
||||
|
|
|||
$ | ||||
|
|
Year ending December 31, |
Annual payment obligation |
|||
2021 |
||||
2022 |
||||
2023 |
||||
2024 |
||||
|
|
|||
$ | ||||
|
|
June 30, 2021 |
December 31, 2020 |
|||||||
Note 1 – Monaco 2014 |
$ | $ | ||||||
Note 2 – Monaco 2016 |
||||||||
Note 3 – MINOSA 1 |
||||||||
Note 4 – Epsilon |
— | |||||||
Note 5 – SMOM |
||||||||
Note 6 – MINOSA 2 |
||||||||
Note 7 – Monaco 2018 |
||||||||
Note 8 – Promissory note |
||||||||
Note 9 – Litigation financing |
||||||||
Note 10 – Payroll Protection Program |
||||||||
Note 11 – Emergency Injury Disaster Loan |
||||||||
Note 12 – Vendor note payable |
||||||||
|
|
|
|
|||||
$ |
$ |
|||||||
|
|
|
|
Tranche 1 | Tranche 2 | Tranche 3 | Tranche 4 | Tranche 5 | Total | |||||||||||||||||||
Promissory Note |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||
Deferred Income (Oceanica Call Option) |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Proceeds |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Tranche 3 | Tranche 4 | Tranche 5 | ||||||||||
Promissory Note |
$ | $ | $ | |||||||||
Beneficial Conversion Feature (“BCF”)* |
— | |||||||||||
|
|
|
|
|
|
|||||||
Proceeds |
$ |
$ |
$ |
|||||||||
|
|
|
|
|
|
• |
the maturity date of the Notes was extended by one year, to July 12, 2020 (the parties are currently in discussions to further extend the maturity date of the Notes); |
• |
the conversion rate of the Notes and the exercise price of the Warrants were modified to $5.756, which represented the “market price” of Odyssey’s common stock as of July 7, 2019, the day before the Second Amendment was signed; |
• |
the Notes are unsecured; |
• |
the Notes are convertible only into shares of Odyssey common stock; and |
• |
the modified Warrants are exercisable at any time until July 8, 2024 to purchase an aggregate of 196,135 shares of our common stock. |
• | the maturity date of the Notes was extended by one year, to | ||
• | the conversion rate of the Notes was modified to $ |
(a) | a first phase, in which the Funder shall make Claims Payments in an aggregate amount no greater than $ |
(b) | a second phase, in which the Funder shall make Claims Payments in an aggregate amount no greater than $ |
(a) | If the Claimholder receives only the Phase I Investment Amount from the Funder, the first Proceeds shall be distributed as follows: |
(i) | |
(ii) | |
(iii) | |
(b) | If the Claimholder exercises its options to receive Tranche A or both Tranche A and Tranche B of the Phase II Investment Amount, the first Proceeds shall be distributed as follows: |
(i) | |
(ii) | |
(iii) | |
(iv) | |
• | The Funder agreed to provide up to $ |
• | A closing fee of $ |
• | A warrant was issued to purchase our common stock which is exercisable for a period of five years beginning on the earlier of (a) the date on which the Claimholder ceases the Subject Claim for any reason other than a full and final arbitral award against the Claimholder or a full and final monetary settlement of the claims or (b) the date on which Proceeds are received and deposited into escrow. The exercise price per share is $ |
• | All other terms in the Restated Agreement are substantially the same as in the original Agreement. |
Convertible Preferred Stock |
Shares |
Price Per Share |
Total Investment |
|||||||||
Series AA-1 |
$ | |
$ | |||||||||
Series AA-2 |
$ | |||||||||||
|
|
|
|
|||||||||
$ |
||||||||||||
|
|
|
|
June 30, 2021 |
December 31, 2020 |
|||||||
“Seattle” project |
$ | |||||||
Galt Resources, LLC (HMS Victory project) |
||||||||
|
|
|
|
|||||
Total revenue participation rights |
$ | $ | ||||||
|
|
|
|
• | No chemicals would be used in the dredging process or released into the sea. |
• | A specialized return down pipe that exceeds international best practices to manage the return of dredged sands close to the seabed, limiting plume or impact to the water column and marine ecosystem (including primary production). |
• | The seabed would be restored after dredging in such a way as to promote rapid regeneration of seabed organisms in dredged areas. |
• | Ecotoxicology tests demonstrated that the dredging and return of sediment to the seabed would not have toxic effects on organisms. |
• | Sound propagation studies concluded that noise levels generated during dredging would be similar to whale-watching vessels, merchant ships and fisherman’s ships that already regularly transit this area, proving the system is not a threat to marine mammals. |
• | Dredging limited to less than one square kilometre each year, which means the project would operate in only a tiny proportion of the concession area each year. |
• | Proven turtle protection measures were incorporated even though the deposit and the dredging activity are much deeper and colder than where turtles feed and live, making material harm to the species unfeasible. |
• | There will be no material impact on local fisheries as fishermen have historically avoided the water column directly above the deposit due to the naturally low occurrence of fish there. |
• | The project would not be visible from the shoreline and would not impact tourism or coastal activities. |
• | Precautionary mitigation measures were incorporated into the development plan in line with best-practice global operational standards. |
• | The technology proposed to recover the phosphate sands has been safely used in Mexican waters for over 20 years on more than 200 projects by ExO’s operating partner, illustrating the hypocrisy of the denial of the environmental permit for the project, especially when one considers that Mexico approved much higher impact dredging projects in areas that its own environmental agency deemed “environmentally sensitive areas” during this same time period. |
• | Article 1102. National Treatment. |
• | Article 1105. Minimum Standard of Treatment; and |
• | Article 1110. Expropriation and compensation. |
• | MERITS: Testimony from independent environmental experts that the environmental impact of ExO’s phosphate project is minimal and readily mitigated by the mitigation measures proposed by ExO. Witnesses also testified that Mexico’s denial of environmental approval by the prior administration was politically motivated and not justified on environmental grounds, and that Mexico granted environmental permits to similar dredging projects in areas that are considered more environmentally sensitive than ExO’s project location. |
• | RESOURCE: An independent certified marine geologist testified as to the size and character of the resource. |
• | OPERATIONAL VIABILITY: Engineering experts testified that the project uses established dredging and processing technology, and the project’s anticipated CAPEX and OPEX was reasonable. |
• | VALUE: A Phosphate market analyst testified that the project’s projected CAPEX and OPEX would make the project one of the lowest cost phosphate rock resources in the world, and damages experts testified the project would be commercially viable and profitable. |
Increase/(Decrease) |
2021 vs. 2020 |
|||||||||||||||
(Dollars in millions) |
2021 |
2020 |
$ |
% |
||||||||||||
Total revenues |
$ | 0.2 | $ | 0.5 | $ | (0.3 | ) | 65 | % | |||||||
|
|
|
|
|
|
|
|
|||||||||
Marketing, general and administrative |
1.7 | 1.3 | 0.4 | 33 | % | |||||||||||
Operations and research |
3.4 | 3.3 | 0.1 | 4 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
$ | 5.1 | $ | 4.6 | $ | 0.6 | 12 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Other income (expense) |
$ | 1.2 | $ | (1.8 | ) | $ | 3.0 | 167 | % | |||||||
|
|
|
|
|
|
|
|
|||||||||
Income tax benefit (provision) |
$ | 0.0 | $ | 0.0 | $ | 0.0 | 0 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Non-controlling interest |
$ | 1.5 | $ | 1.7 | $ | (0.2 | ) | 11 | % | |||||||
|
|
|
|
|
|
|
|
|||||||||
Net income (loss) |
$ | (2.2 | ) | $ | (4.1 | ) | $ | (1.9 | ) | 46 | % | |||||
|
|
|
|
|
|
|
|
Increase/(Decrease) |
2021 vs. 2020 |
|||||||||||||||
(Dollars in millions) |
2021 |
2020 |
$ |
% |
||||||||||||
Total revenues |
$ | 0.5 | $ | 1.5 | $ | (1.1 | ) | 69 | % | |||||||
|
|
|
|
|
|
|
|
|||||||||
Marketing, general and administrative |
3.0 | 2.7 | 0.3 | 12 | % | |||||||||||
Operations and research |
5.2 | 5.7 | (0.5 | ) | 9 | % | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
$ | 8.2 | $ | 8.4 | $ | (0.2 | ) | 2 | % | |||||||
|
|
|
|
|
|
|
|
|||||||||
Other income (expense) |
$ | (1.1 | ) | $ | (3.3 | ) | $ | 2.1 | 65 | % | ||||||
|
|
|
|
|
|
|
|
|||||||||
Income tax benefit (provision) |
$ | 0.0 | $ | 0.0 | $ | 0.0 | 0 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Non-controlling interest |
$ | 2.9 | $ | 3.2 | $ | (0.2 | ) | 8 | % | |||||||
|
|
|
|
|
|
|
|
|||||||||
Net income (loss) |
$ | (5.9 | ) | $ | (7.0 | ) | $ | 1.0 | 15 | % | ||||||
|
|
|
|
|
|
|
|
Three Months Ended |
||||||||
(In thousands) |
June 30, 2021 |
June 30, 2020 |
||||||
Summary of Cash Flows: |
||||||||
Net cash (used) by operating activities |
$ | (2,838 | ) | $ | (2,595 | ) | ||
Net cash (used) provided by investing activities |
(14 | ) | — | |||||
Net cash provided by financing activities |
1,475 | 2,606 | ||||||
|
|
|
|
|||||
Net (decrease) increase in cash and cash equivalents |
$ | (1,377 | ) | $ | 11 | |||
Beginning cash and cash equivalents |
6,163 | 213 | ||||||
|
|
|
|
|||||
Ending cash and cash equivalents |
$ | 4,786 | $ | 224 | ||||
|
|
|
|
Series |
No. of Shares |
Price per Share |
||||||
Series AA-1 |
8,427,004 | $ | 12.00 | |||||
Series AA-2 |
7,223,145 | $ | 6.00 |
Date |
No. Series AA-1 Shares |
Total Purchase Price |
||||||
March 1, 2016 |
1,806,989 | $ | 21,683,868 | |||||
September 1, 2016 |
1,806,989 | $ | 21,683,868 | |||||
March 1, 2017 |
1,517,871 | $ | 18,214,446 | |||||
March 1, 2018 |
378,488 | $ | 4,541,856 |
(c) | a first phase, in which the Funder shall make Claims Payments in an aggregate amount no greater than $1,500,000 for the payment of antecedent and ongoing costs (“Phase I Investment Amount”); and |
(d) | a second phase, in which the Funder shall make Claims Payments in an aggregate amount no greater than $5,000,000 for the purposes of pursuing the Subject Claim to a final award (“Phase II Investment Amount”). |
(a) | If the Claimholder receives only the Phase I Investment Amount from the Funder, the first Proceeds shall be distributed as follows: |
(i) | first, 100.0% to the Funder, until the cumulative amount distributed to the Funder equals the total Claims Payments paid by the Funder under Phase I; |
(ii) | second, 100.0% to the Funder until the cumulative amount distributed to the Funder equals an IRR of 20% of Claims Payments paid by the Funder under Phase I (“Phase I Compensation”), per annum; and |
(iii) | thereafter, 100.0% to the Claimholder. |
(b) | If the Claimholder exercises its options to receive Tranche A or both Tranche A and Tranche B of the Phase II Investment Amount, the first Proceeds shall be distributed as follows: |
(i) | first, 100.0% to the Funder until the cumulative amount distributed to the Funder equals the total Claims Payments paid by the Funder under Phases I and II; |
(ii) | second, 100.0% to the Funder until the cumulative amount distributed to the Funder equals an additional 300.0% of Phase I Investment Amount; plus an additional 300% of the Tranche A Committed Amount (i.e. 300.0% of $3.5 million), less any amounts remaining of the Tranche A Committed Amount that the Funder did not pay as Claims Payments; plus an additional 300.0% of the Tranche B Committed Amount (i.e. 300.0% of $1.5 million), if the Claimholder exercises the Tranche B funding option, less any amounts remaining of the Tranche B Committed Amount that the Funder did not pay as Claims Payments; |
(iii) | third, for each $10,000 in specified fees and expenses paid by the Funder under Phase I and Phase II and any amounts over each $10,000 of the Tranche A Committed Amount and the Tranche B Committed Amount (if the Claimholder exercises the Tranche B funding option), 0.01% of the total Proceeds from any recoveries after repayment of (i) and (ii) above, to the Funder; and |
(iv) | thereafter, 100% to the Claimholder. |
• | The Funder has agreed to provide up to $2.2 million in Arbitration Support Funds for the purpose of paying the Claimholder’s litigation support costs in connection with Subject Claim; |
• | A closing fee of $200,000 has been retained by the Funder in connection with due diligence and other transaction costs incurred by the Funder; |
• | A warrant was issued to purchase our common stock which is exercisable for a period of five years beginning on the earlier of (a) the date on which the Claimholder ceases the Subject Claim for any reason other than a full and final arbitral award against the Claimholder or a full and final monetary settlement of the claims or (b) the date on which Proceeds are received and deposited into escrow. The exercise price per share is $3.99, and the Funder can exercise the warrant to purchase the number of shares of our common stock equal to the dollar amount of Arbitration Support Funds provided to us pursuant to the Restated Agreement divided by the exercise price per share (subject to customary adjustments and limitations); and |
• | All other terms in the Restated Agreement are substantially the same as in the original Agreement. |
ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
ITEM 4. |
CONTROLS AND PROCEDURES |
ITEM 1. |
Legal Proceedings |
ITEM 1A. |
Risk Factors |
ITEM 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
ITEM 4. |
Mine Safety Disclosures |
ITEM 5. |
Other Information |
ITEM 6. |
Exhibits |
31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Filed herewith electronically) | |
31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Filed herewith electronically) | |
32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 (Filed herewith electronically) | |
32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (Filed herewith electronically) | |
101 | Interactive Data File | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
ODYSSEY MARINE EXPLORATION, INC. | ||||||
Date: August 13, 2021 | By: | /s/ Christopher E. Jones | ||||
Christopher E. Jones, as Chief Financial Officer and Authorized Officer |